Dose-Finding study of landiolol hydrochloride

A short-acting Β1-Blocker for controlling heart rate during coronary computed-Tomography angiography in japan

Masaharu Hirano, Kazuhiro Hara, Yuji Ikari, Masahiro Jinzaki, Misako Iino, Chikuma Hamada, Sachio Kuribayashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Coronary computedtomography angiography (CCTA) has high diagnostic performance, but it sometimes does not allow evaluation because of artifacts. Currently, the use of a β -blocker is recommended to prevent motion artifacts, but the b-blocker (metoprolol, propranolol, etc.) commonly used has a slow onset and long duration of action. andiolol hydrochloride is an intravenous β 1-blocker with a very short half-life. We investigated the efficacy and optimal dose of this drug for reduction of heart rate in patients undergoing CCTA. Methods: Eighty-seven subjects with ischemic heart disease were divided into three groups to receive landiolol hydrochloride at a dose of 0.125 (Group L), 0.25 (Group M), or 0.5 mg/kg (Group H). CCTA was performed at 3-7 min after administration, and heart rate, blood pressure, and image quality were assessed. Results: Heart rate decreased rapidly after completion of landiolol hydrochloride administration in all groups, with a heart rate reduction of 15.55 ± 6.56% in Group L, 16.48 ± 7.80% in Group M, and 21.49 ± 6.13%in Group H (Group L vs Group H, P = 0.0008; Group M vs Group H, P = 0.0109). Since there was no significant difference in heart rate during imaging among the three groups, although there was a significant difference between groups L and H and groups M and H in terms of percent change in heart rate, coronary stenosis was diagnosable in all groups with no significant difference. Conclusion: Landiolol hydrochloride showed a rapid onset and short b-blocking effect, and was most effective at a dose of 0.5 mg/kg. However, the diagnosable proportion had no significant differences among the three groups in CCTA. Therefore, the clinically recommended dose was 0.125 mg/kg or less, considering the heart rate of patients with suspected coronary stenosis during CCTA.

Original languageEnglish
Pages (from-to)803-818
Number of pages16
JournalAdvances in Therapy
Volume30
Issue number9
DOIs
Publication statusPublished - 2013 Sep

Fingerprint

Japan
Heart Rate
Coronary Angiography
Coronary Stenosis
Artifacts
Metoprolol
Computed Tomography Angiography
landiolol
Propranolol
Myocardial Ischemia
Half-Life
Blood Pressure
Pharmaceutical Preparations

Keywords

  • Β-Blocker
  • Angiography
  • Cardiology
  • CCTA
  • Coronary computed-tomography angiography
  • Image quality
  • Landiolol hydrochloride
  • MDCT
  • Motion artifact
  • Multidetector row computed tomography

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Dose-Finding study of landiolol hydrochloride : A short-acting Β1-Blocker for controlling heart rate during coronary computed-Tomography angiography in japan. / Hirano, Masaharu; Hara, Kazuhiro; Ikari, Yuji; Jinzaki, Masahiro; Iino, Misako; Hamada, Chikuma; Kuribayashi, Sachio.

In: Advances in Therapy, Vol. 30, No. 9, 09.2013, p. 803-818.

Research output: Contribution to journalArticle

Hirano, Masaharu ; Hara, Kazuhiro ; Ikari, Yuji ; Jinzaki, Masahiro ; Iino, Misako ; Hamada, Chikuma ; Kuribayashi, Sachio. / Dose-Finding study of landiolol hydrochloride : A short-acting Β1-Blocker for controlling heart rate during coronary computed-Tomography angiography in japan. In: Advances in Therapy. 2013 ; Vol. 30, No. 9. pp. 803-818.
@article{a019e0e2e7f74438ad9e110788566bf9,
title = "Dose-Finding study of landiolol hydrochloride: A short-acting Β1-Blocker for controlling heart rate during coronary computed-Tomography angiography in japan",
abstract = "Introduction: Coronary computedtomography angiography (CCTA) has high diagnostic performance, but it sometimes does not allow evaluation because of artifacts. Currently, the use of a β -blocker is recommended to prevent motion artifacts, but the b-blocker (metoprolol, propranolol, etc.) commonly used has a slow onset and long duration of action. andiolol hydrochloride is an intravenous β 1-blocker with a very short half-life. We investigated the efficacy and optimal dose of this drug for reduction of heart rate in patients undergoing CCTA. Methods: Eighty-seven subjects with ischemic heart disease were divided into three groups to receive landiolol hydrochloride at a dose of 0.125 (Group L), 0.25 (Group M), or 0.5 mg/kg (Group H). CCTA was performed at 3-7 min after administration, and heart rate, blood pressure, and image quality were assessed. Results: Heart rate decreased rapidly after completion of landiolol hydrochloride administration in all groups, with a heart rate reduction of 15.55 ± 6.56{\%} in Group L, 16.48 ± 7.80{\%} in Group M, and 21.49 ± 6.13{\%}in Group H (Group L vs Group H, P = 0.0008; Group M vs Group H, P = 0.0109). Since there was no significant difference in heart rate during imaging among the three groups, although there was a significant difference between groups L and H and groups M and H in terms of percent change in heart rate, coronary stenosis was diagnosable in all groups with no significant difference. Conclusion: Landiolol hydrochloride showed a rapid onset and short b-blocking effect, and was most effective at a dose of 0.5 mg/kg. However, the diagnosable proportion had no significant differences among the three groups in CCTA. Therefore, the clinically recommended dose was 0.125 mg/kg or less, considering the heart rate of patients with suspected coronary stenosis during CCTA.",
keywords = "Β-Blocker, Angiography, Cardiology, CCTA, Coronary computed-tomography angiography, Image quality, Landiolol hydrochloride, MDCT, Motion artifact, Multidetector row computed tomography",
author = "Masaharu Hirano and Kazuhiro Hara and Yuji Ikari and Masahiro Jinzaki and Misako Iino and Chikuma Hamada and Sachio Kuribayashi",
year = "2013",
month = "9",
doi = "10.1007/s12325-013-0053-0",
language = "English",
volume = "30",
pages = "803--818",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "9",

}

TY - JOUR

T1 - Dose-Finding study of landiolol hydrochloride

T2 - A short-acting Β1-Blocker for controlling heart rate during coronary computed-Tomography angiography in japan

AU - Hirano, Masaharu

AU - Hara, Kazuhiro

AU - Ikari, Yuji

AU - Jinzaki, Masahiro

AU - Iino, Misako

AU - Hamada, Chikuma

AU - Kuribayashi, Sachio

PY - 2013/9

Y1 - 2013/9

N2 - Introduction: Coronary computedtomography angiography (CCTA) has high diagnostic performance, but it sometimes does not allow evaluation because of artifacts. Currently, the use of a β -blocker is recommended to prevent motion artifacts, but the b-blocker (metoprolol, propranolol, etc.) commonly used has a slow onset and long duration of action. andiolol hydrochloride is an intravenous β 1-blocker with a very short half-life. We investigated the efficacy and optimal dose of this drug for reduction of heart rate in patients undergoing CCTA. Methods: Eighty-seven subjects with ischemic heart disease were divided into three groups to receive landiolol hydrochloride at a dose of 0.125 (Group L), 0.25 (Group M), or 0.5 mg/kg (Group H). CCTA was performed at 3-7 min after administration, and heart rate, blood pressure, and image quality were assessed. Results: Heart rate decreased rapidly after completion of landiolol hydrochloride administration in all groups, with a heart rate reduction of 15.55 ± 6.56% in Group L, 16.48 ± 7.80% in Group M, and 21.49 ± 6.13%in Group H (Group L vs Group H, P = 0.0008; Group M vs Group H, P = 0.0109). Since there was no significant difference in heart rate during imaging among the three groups, although there was a significant difference between groups L and H and groups M and H in terms of percent change in heart rate, coronary stenosis was diagnosable in all groups with no significant difference. Conclusion: Landiolol hydrochloride showed a rapid onset and short b-blocking effect, and was most effective at a dose of 0.5 mg/kg. However, the diagnosable proportion had no significant differences among the three groups in CCTA. Therefore, the clinically recommended dose was 0.125 mg/kg or less, considering the heart rate of patients with suspected coronary stenosis during CCTA.

AB - Introduction: Coronary computedtomography angiography (CCTA) has high diagnostic performance, but it sometimes does not allow evaluation because of artifacts. Currently, the use of a β -blocker is recommended to prevent motion artifacts, but the b-blocker (metoprolol, propranolol, etc.) commonly used has a slow onset and long duration of action. andiolol hydrochloride is an intravenous β 1-blocker with a very short half-life. We investigated the efficacy and optimal dose of this drug for reduction of heart rate in patients undergoing CCTA. Methods: Eighty-seven subjects with ischemic heart disease were divided into three groups to receive landiolol hydrochloride at a dose of 0.125 (Group L), 0.25 (Group M), or 0.5 mg/kg (Group H). CCTA was performed at 3-7 min after administration, and heart rate, blood pressure, and image quality were assessed. Results: Heart rate decreased rapidly after completion of landiolol hydrochloride administration in all groups, with a heart rate reduction of 15.55 ± 6.56% in Group L, 16.48 ± 7.80% in Group M, and 21.49 ± 6.13%in Group H (Group L vs Group H, P = 0.0008; Group M vs Group H, P = 0.0109). Since there was no significant difference in heart rate during imaging among the three groups, although there was a significant difference between groups L and H and groups M and H in terms of percent change in heart rate, coronary stenosis was diagnosable in all groups with no significant difference. Conclusion: Landiolol hydrochloride showed a rapid onset and short b-blocking effect, and was most effective at a dose of 0.5 mg/kg. However, the diagnosable proportion had no significant differences among the three groups in CCTA. Therefore, the clinically recommended dose was 0.125 mg/kg or less, considering the heart rate of patients with suspected coronary stenosis during CCTA.

KW - Β-Blocker

KW - Angiography

KW - Cardiology

KW - CCTA

KW - Coronary computed-tomography angiography

KW - Image quality

KW - Landiolol hydrochloride

KW - MDCT

KW - Motion artifact

KW - Multidetector row computed tomography

UR - http://www.scopus.com/inward/record.url?scp=84894304204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894304204&partnerID=8YFLogxK

U2 - 10.1007/s12325-013-0053-0

DO - 10.1007/s12325-013-0053-0

M3 - Article

VL - 30

SP - 803

EP - 818

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 9

ER -